Abstract
Purpose
This work evaluated the feasibility of combining insulin PEGylation with pH responsive hydrogels for oral insulin delivery.
Methods
A mono-substituted PEG–insulin conjugate was synthesized and purified. The site of conjugation was determined by MALDI-TOF MS. Uptake and release of PEGylated insulin was performed in complexation hydrogels to simulate oral dosing. The bioactivity of the conjugate and PK/PD profile was measured in vivo in rats.
Results
PEGylation was confirmed to be specifically located at the amino terminus of the B-chain of insulin. Higher loading efficiency was achieved with PEGylated insulin than regular human insulin in pH responsive hydrogels. The release of PEGylated insulin was lower than that of human insulin at all pH levels considered. Full retention of bioactivity of the PEG–insulin conjugate was confirmed by intravenous dosing while subcutaneous dosing exhibited a relative hypoglycemic effect 127.8% that of human insulin.
Conclusions
Polyethylene glycol conjugated specifically to the amino terminus of the B-chain of insulin maintained the bioactivity of the protein and significantly extended the duration of the hypoglycemic effect. Used in combination with pH responsive hydrogels, PEGylated insulin has significant potential for oral delivery.
Similar content being viewed by others
Abbreviations
- ELISA:
-
enzyme-linked immunosorbent assay
- FPLC:
-
fast protein liquid chromatography
- IEC:
-
ion exchange chromatography
- MAA:
-
methacrylic acid
- MALDI-TOF MS:
-
matrix-assisted laser desorption ionization time of flight mass spectrometry
- PEG:
-
polyethylene glycol
- PEGDMA:
-
polyethylene glycol dimethacrylate
- PEGMA:
-
polyethylene glycol monomethacrylate monomethyl ether
- P(MAA-g-EG):
-
poly(methacrylic acid-graft-ethylene glycol)
- RP-HPLC:
-
reverse-phase high performance liquid chromatography
References
A. M. Lowman, M. Morishita, M. Kajita, T. Nagai, and N. A. Peppas. Oral delivery of insulin using pH-responsive complexation gels. J. Pharm. Sci. 88:933–937 (1999). Medline. doi:10.1021/js980337n.
A. M. Lowman, and N. A. Peppas. Analysis of the complexation/decomplexation phenomena in graft copolymer networks. Macromolecules. 30:4959–4965 (1997). doi:10.1021/ma970399k.
N. A. Peppas. Devices based on intelligent biopolymers for oral protein delivery. Int. J. Pharm. 277:11–17 (2004). doi:10.1016/j.ijpharm.2003.03.001.
N. A. Peppas, P. Bures, W. Leobandung, and H. Ichikawa. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 50:27–46 (2000). doi:10.1016/S0939-6411(00)00090-4.
N. A. Peppas, K. B. Keys, M. Torres-Lugo, and A. M. Lowman. Poly(ethylene glycol)-containing hydrogels in drug delivery. J. Control. Release. 62:81–87 (1999). doi:10.1016/S0168-3659(99)00027-9.
T. Yamagata, M. Morishita, N. J. Kavimandan, K. Nakamura, Y. Fukuoka, K. Takayama, and N. A. Peppas. Characterization of insulin protection properties of complexation hydrogels in gastric and intestinal enzyme fluids. J. Control Release. 112:343–349 (2006). doi:10.1016/j.jconrel.2006.03.005.
B. Kim, and N. A. Peppas. In vitro release behavior and stability of insulin in complexation hydrogels as oral drug delivery carriers. Int. J. Pharm. 266:29–37 (2003). doi:10.1016/S0378-5173(03)00378-8.
F. Madsen, and N. A. Peppas. Complexation graft copolymer networks: swelling properties, calcium binding and proteolytic enzyme inhibition. Biomaterials. 20:1701–1708 (1999). doi:10.1016/S0142-9612(99)00071-X.
E. Perakslis, A. Tuesca, and A. Lowman. Complexation hydrogels for oral protein delivery: an in vitro assessment of the insulin transport-enhancing effects following dissolution in simulated digestive fluids. J. Biomater. Sci. Polym. Ed. 18:1475–1490 (2007).
K. Nakamura, R. J. Murray, J. I. Joseph, N. A. Peppas, M. Morishita, and A. M. Lowman. Oral insulin delivery using P(MAA-g-EG) hydrogels: effects of network morphology on insulin delivery characteristics. J. Control Release. 95:589–599 (2004). doi:10.1016/j.jconrel.2003.12.022.
T. Goto, M. Morishita, N. J. Kavimandan, K. Takayama, and N. A. Peppas. Gastrointestinal transit and mucoadhesive characteristics of complexation hydrogels in rats. J. Pharm. Sci. 95:462–469 (2006). doi:10.1002/jps.20566.
M. Torres-Lugo, M. Garcia, R. Record, and N. A. Peppas. pH-Sensitive hydrogels as gastrointestinal tract absorption enhancers: transport mechanisms of salmon calcitonin and other model molecules using the Caco-2 cell model. Biotechnol. Prog. 18:612–616 (2002). doi:10.1021/bp0101379.
H. Ichikawa, and N. A. Peppas. Novel complexation hydrogels for oral peptide delivery: in vitro evaluation of their cytocompatibility and insulin-transport enhancing effects using Caco-2 cell monolayers. J. Biomed. Mater. Res. A. 67:609–617 (2003). doi:10.1002/jbm.a.10128.
M. Morishita, T. Goto, K. Nakamura, A. M. Lowman, K. Takayama, and N. A. Peppas. Novel oral insulin delivery systems based on complexation polymer hydrogels: single and multiple administration studies in type 1 and 2 diabetic rats. J. Control Release. 110:587–594 (2006). doi:10.1016/j.jconrel.2005.10.029.
A. Tuesca, K. Nakamura, M. Morishita, J. Joseph, N. Peppas, and A. Lowman. Complexation hydrogels for oral insulin delivery: effects of polymer dosing on in vivo efficacy. J. Pharm. Sci. 97:2607–2618 (2008). doi:10.1002/jps.21184.
S. Zalipsky. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv. Drug Deliv. Rev. 16:157–182 (1995). doi:10.1016/0169-409X(95)00023-Z.
F. M. Veronese, and G. Pasut. PEGylation, successful approach to drug delivery. Drug Discov. Today. 10:1451–1458 (2005). doi:10.1016/S1359-6446(05)03575-0.
M. J. Roberts, M. D. Bentley, and J. M. Harris. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54:459–476 (2002). doi:10.1016/S0169-409X(02)00022-4.
R. B. Greenwald, Y. H. Choe, J. McGuire, and C. D. Conover. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55:217–250 (2003). doi:10.1016/S0169-409X(02)00180-1.
D. G. Lindsay, and S. Shall. The acetylation of insulin. Biochem. J. 121:737–745 (1971).
P. Calceti, S. Salmaso, G. Walker, and A. Bernkop-Schnurch. Development and in vivo evaluation of an oral insulin–PEG delivery system. Eur. J. Pharm. Sci. 22:315–323 (2004). doi:10.1016/j.ejps.2004.03.015.
M. Baudyš, T. Uchio, L. Hovgaard, E. F. Zhu, T. Avramoglou, M. Jozefowicz, B. Ríhová, J. Y. Park, H. K. Lee, and S. W. Kim. Glycosylated insulins. J. Control Release. 36:151–157 (1995). doi:10.1016/0168-3659(95)00022-Z.
M. Baudyš, T. Uchio, D. Mix, D. Wilson, and S. W. Kim. Physical stabilization of insulin by glycosylation. J. Pharm. Sci. 84:28–33 (1995). doi:10.1002/jps.2600840108.
T. Uchio, M. Baudys, F. Liu, S. C. Song, and S. W. Kim. Site-specific insulin conjugates with enhanced stability and extended action profile. Adv. Drug Deliv. Rev. 35:289–306 (1999). doi:10.1016/S0169-409X(98)00078-7.
K. Hinds, J. J. Koh, L. Joss, F. Liu, M. Baudys, and S. W. Kim. Synthesis and characterization of poly(ethylene glycol)–insulin conjugates. Bioconjug. Chem. 11:195–201 (2000). doi:10.1021/bc9901189.
J. S. Patton, M. C. Kuo, J. M. Harris, C. Leach, K. Perkins, and B. Bueche. Compositions of chemically modified insulin, Patent # 6,890,518 B2 United States Patent Office, Nektar Therapeutics, USA, 2005.
A. Sood, and R. Panchagnula. Peroral route: an opportunity for protein and peptide drug delivery. Chem. Rev. 101:3275–3303 (2001). doi:10.1021/cr000700 m.
J. Markussen, J. Halstrom, F. C. Wiberg, and L. Schaffer. Immobilized insulin for high capacity affinity chromatography of insulin receptors. J. Biol. Chem. 266:18814–18818 (1991).
W. Konigsberg. Reduction of disulfide bonds in proteins with dithiolthreitol. Methods Enzymol. 25:185–188 (1972). doi:10.1016/S0076-6879(72)25015-7.
A. Tuesca, and A. Lowman. Elucidation of the mechanism of enhanced insulin uptake and release from pH responsive hydrogels. Macromol. Symp. 266:101–107 (2008). doi:10.1002/masy.200850619.
A. Volund. Conversion of insulin units to SI units. Am. J. Clin. Nutr. 58:714–715 (1993).
F. M. Veronese. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 22:405–417 (2001). doi:10.1016/S0142-9612(00)00193-9.
J. C. Pickup and G. Williams, Eds. Textbook of Diabetes, Blackwell Science Ltd., Malden, MA, 1997.
M. S. Nolte, and J. H. Karam. Pancreatic Hormones & Anitdiabetic Drugs. In B. G. Katzung (ed.), Basic and Clinical Pharmacology, 10McGraw-Hill, New York, 2007.
K. D. Hinds, and S. W. Kim. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 54:505–530 (2002). doi:10.1016/S0169-409X(02)00025-X.
ACKNOWLEDGMENTS
This work was supported by funding from NIH Grant # DGE-0221664. Additional funding was provided by NSF grant number R01-EB000246.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tuesca, A.D., Reiff, C., Joseph, J.I. et al. Synthesis, Characterization and In Vivo Efficacy of PEGylated Insulin for Oral Delivery with Complexation Hydrogels. Pharm Res 26, 727–739 (2009). https://doi.org/10.1007/s11095-008-9816-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-008-9816-8